Citrate in autosomal dominant polycystic kidney disease: biomarker or therapeutic agent?

IF 2.2 3区医学 Q3 PERIPHERAL VASCULAR DISEASE

Current Opinion in Nephrology and Hypertension Pub Date : 2025-03-01 Epub Date: 2024-11-13 DOI:10.1097/MNH.0000000000001047

Daniel Ribeiro Rocha, Ana Cristina Carvalho Matos, Ita Pfeferman Heilberg

{"title":"Citrate in autosomal dominant polycystic kidney disease: biomarker or therapeutic agent?","authors":"Daniel Ribeiro Rocha, Ana Cristina Carvalho Matos, Ita Pfeferman Heilberg","doi":"10.1097/MNH.0000000000001047","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review highlights the latest findings regarding hypocitraturia in autosomal dominant polycystic kidney disease (ADPKD), from both experimental and clinical studies, exploring the underlying pathophysiology and potential therapeutic approach.Recent findings: Experimental studies have shown that the lodging of microcrystals in the tubules can trigger cyst formation and growth in polycystic kidney disease (PKD). ADPKD patients are prone to developing hypocitraturia in early stages, which could predispose to calcium microcrystal formation. Low urinary citrate excretion has been associated with a more rapid decline in eGFR and poorer renal survival in ADPKD patients. Animal studies employing citrate supplementation have shown promising effects on preserving the decline in estimated glomerular filtration rate (eGFR) and cyst growth.Summary: Current knowledge suggests that urinary citrate could be incorporated into existing prognostic markers for disease progression and potential adjuvant therapy in ADPKD, but further clinical studies to support such hypothesis must be undertaken.","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":"34 2","pages":"138-142"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Nephrology and Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MNH.0000000000001047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review highlights the latest findings regarding hypocitraturia in autosomal dominant polycystic kidney disease (ADPKD), from both experimental and clinical studies, exploring the underlying pathophysiology and potential therapeutic approach.

Recent findings: Experimental studies have shown that the lodging of microcrystals in the tubules can trigger cyst formation and growth in polycystic kidney disease (PKD). ADPKD patients are prone to developing hypocitraturia in early stages, which could predispose to calcium microcrystal formation. Low urinary citrate excretion has been associated with a more rapid decline in eGFR and poorer renal survival in ADPKD patients. Animal studies employing citrate supplementation have shown promising effects on preserving the decline in estimated glomerular filtration rate (eGFR) and cyst growth.

Summary: Current knowledge suggests that urinary citrate could be incorporated into existing prognostic markers for disease progression and potential adjuvant therapy in ADPKD, but further clinical studies to support such hypothesis must be undertaken.

查看原文本刊更多论文

常染色体显性多囊肾病的柠檬酸盐：生物标志物还是治疗剂？

综述目的：本文综述了常染色体显性多囊肾病（ADPKD）的实验和临床研究的最新发现，探讨了其潜在的病理生理和潜在的治疗方法。最新发现：实验研究表明，在多囊肾病（PKD）中，微晶体在小管中倒伏可引发囊肿的形成和生长。ADPKD患者早期易出现低尿症，易发生钙微晶形成。在ADPKD患者中，低尿柠檬酸盐排泄与eGFR的快速下降和较差的肾脏生存有关。动物研究表明，枸橼酸补充剂对保持肾小球滤过率（eGFR）和囊肿生长的下降有很好的效果。总结：目前的知识表明，尿柠檬酸盐可以作为ADPKD疾病进展和潜在辅助治疗的现有预后标志物，但必须进行进一步的临床研究来支持这一假设。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Nephrology and Hypertension 医学-泌尿学与肾脏学

CiteScore

5.70

自引率

6.20%

发文量

132

审稿时长

6-12 weeks

期刊介绍： A reader-friendly resource, Current Opinion in Nephrology and Hypertension provides an up-to-date account of the most important advances in the field of nephrology and hypertension. Each issue contains either two or three sections delivering a diverse and comprehensive coverage of all the key issues, including pathophysiology of hypertension, circulation and hemodynamics, and clinical nephrology. Current Opinion in Nephrology and Hypertension is an indispensable journal for the busy clinician, researcher or student.